As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a number of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Rituximab
-
-
The Patent Trial and Appeal Board (“the Board”) has decided not to institute inter partes review (“IPR”) on two patents owned by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sandoz announced last week that the FDA issued a complete response letter for its proposed biosimilar to rituximab. In the announcement,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Celltrion filed three petitions seeking inter partes review (“IPR”) of two patents related to Genentech and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, Pfizer, Inc. (“Pfizer”) filed two petitions for inter partes review (“IPR”) of two patents related to Genentech and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Biologic drugs are quickly reshaping the pharmaceutical landscape as they dominate the drug market in annual sales revenue. Abbvie’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion announced last week that its Biologics License Application (“BLA”) for CT-P10, a biosimilar to Biogen and Genentech’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]